Comparison
Linaclotid vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
851199-59-2
80714-61-0
Molecular weight
1526.74 g/mol
813.92 g/mol
Half-life
no data
0.3 h
Sequence
no data
Met-Glu-His-Phe-Pro-Gly-ProMechanism of action
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
0
4
of which in humans
0
2
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Linaclotid and Semax?
- Linaclotid is classified as "Research other", while Semax is classified as "Research other". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Linaclotid or Semax?
- The highest available evidence level is "Human RCT" for Linaclotid and "Human trial" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Linaclotid and Semax in Germany and the United States?
- Germany: Linaclotid — Prescription, Semax — Unapproved. United States: Linaclotid — Prescription, Semax — Unapproved. These are factual summaries with source and review date on the individual pages.